Trexquant Investment LP Myovant Sciences Ltd. Transaction History

Trexquant Investment LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$11.6 - $20.44 $530,630 - $935,007	45,744 New	45,744 $822,000
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $144,252 - $207,886	-12,676 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $181,393 - $302,576	12,676 New	12,676 $197,000
Q3 2021 Nov 12, 2021	SELL	$18.94 - $26.99 $330,806 - $471,407	-17,466 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$17.07 - $24.56 $298,144 - $428,964	17,466 New	17,466 $398,000
Q1 2021 May 13, 2021	SELL	$20.46 - $25.18 $602,096 - $740,997	-29,428 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$13.8 - $27.62 $406,106 - $812,801	29,428 New	29,428 $813,000
Q3 2020 Nov 06, 2020	SELL	$14.05 - $22.6 $533,717 - $858,506	-37,987 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$7.34 - $20.84 $278,824 - $791,649	37,987 New	37,987 $783,000
Q1 2020 May 08, 2020	SELL	$6.55 - $14.76 $114,258 - $257,473	-17,444 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$4.2 - $19.21 $27,442 - $125,518	6,534 Added 59.89%	17,444 $271,000
Q3 2019 Nov 08, 2019	BUY	$5.19 - $9.46 $56,622 - $103,208	10,910 New	10,910 $57,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.